Product image of Myoview (Tetrofosmin) supplied by GNH India

Myoview

Active Ingredient:
Tetrofosmin
Origin:
EU

Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables myocardial perfusion imaging to assess coronary artery disease in patients undergoing cardiac stress testing.

GNH India supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Manufacturer / TM Owner

Ge Healthcare As

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myoview is a radiopharmaceutical used in cardiac imaging to evaluate myocardial blood flow and detect coronary artery disease.

  • Myocardial perfusion imaging: provides quantitative assessment of regional blood flow to the heart muscle.
  • Detection of coronary artery disease: helps identify obstructive lesions by comparing stress and rest perfusion.
  • Stress and rest cardiac SPECT: enables visualization of perfusion differences under pharmacologic or exercise stress and at rest.

How It Works

  • After intravenous injection, tetrofosmin distributes proportionally to myocardial blood flow and accumulates within the mitochondria of viable cardiac myocytes. The localized radioactivity is then captured by single‑photon emission computed tomography (SPECT), producing high‑resolution images of perfusion patterns that reflect coronary artery patency.

Side Effects

Myoview may cause a range of adverse reactions following administration.

Common Side Effects

  • Nausea: mild to moderate discomfort after injection.
  • Flushing: transient warmth or redness of the skin.
  • Headache: mild to moderate intensity.
  • Dizziness or light‑headedness.
  • Injection‑site pain or irritation.
  • Mild hypotension.

Serious or Rare Side Effects

  • Severe allergic reaction (anaphylaxis): rapid onset of airway swelling, rash, or shock.
  • Life‑threatening arrhythmia: abnormal heart rhythm requiring immediate care.
  • Marked hypotension: sudden drop in blood pressure.
  • Myocardial infarction: rare occurrence of heart attack post‑administration.
  • Pulmonary edema: fluid accumulation in the lungs.
  • Death: extremely rare but reported in severe reactions.

Precautions & Warnings

Prior to Myoview administration, clinicians should consider several safety measures.

  • Patient assessment: evaluate renal function and overall cardiac status.
  • Contraindications: avoid in individuals with known hypersensitivity to tetrofosmin or its excipients.
  • Pregnancy: use only if essential, as safety data are limited.
  • Breastfeeding: discontinue nursing or discontinue the drug, based on clinical judgment.
  • Drug interactions: review concurrent medications that affect myocardial blood flow.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Myoview may interact with other agents that influence myocardial perfusion or radiotracer distribution.

Major Interactions (Avoid)

  • Dipyridamole stress agents: concurrent use can alter tracer uptake.
  • Other nuclear imaging agents: administration within 24 hours may cause cross‑interference.
  • High‑dose caffeine: may blunt stress‑induced perfusion changes.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may reduce stress‑induced heart rate response.
  • Calcium channel blockers: can modify coronary vasodilation.
  • Nitrates: may affect myocardial blood flow patterns.
  • Antihypertensives: monitor blood pressure during imaging.
  • ACE inhibitors or ARBs: observe for altered perfusion signals.

Frequently Asked Questions

Myoview is used as a cardiac imaging agent for myocardial perfusion scintigraphy. It helps physicians evaluate blood flow to the heart muscle during stress and rest conditions, facilitating the detection of coronary artery disease and assessment of myocardial viability.

Tetrofosmin is a lipophilic radiotracer that enters cardiac cells in proportion to blood flow. Once inside, it localizes in the mitochondria of viable myocytes. The emitted gamma radiation is captured by SPECT cameras, producing detailed images of regional perfusion.

The administered activity of Myoview is determined by the prescribing physician based on the imaging protocol, patient weight, and equipment specifications. The dose is delivered as a single intravenous injection immediately before the stress or rest imaging phase.

Safety data for tetrofosmin in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Myoview, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Myoview (tetrofosmin) and technetium‑99m sestamibi are both technetium‑based perfusion tracers with similar imaging quality. Compared with thallium‑201, tetrofosmin offers lower radiation dose, faster imaging protocols, and better image resolution, making it a preferred choice in many modern nuclear cardiology labs.

Myoview must be stored refrigerated at 2–8 °C, protected from light, and kept in its original container. It should not be frozen or shaken. Before use, allow the vial to reach room temperature if required by the imaging protocol.

Myoview is administered by a qualified healthcare professional as an intravenous bolus injection. The injection is typically performed immediately before the stress or rest phase of a SPECT study, and imaging begins shortly after the tracer distributes within the myocardium.

Serious risks, although rare, include severe allergic reactions (anaphylaxis), life‑threatening arrhythmias, marked hypotension, myocardial infarction, and pulmonary edema. Patients should be monitored closely during and after injection, and emergency measures must be readily available.

Myoview should not be given to individuals with a known hypersensitivity to tetrofosmin or any of its excipients. It is also contraindicated in patients with severe renal impairment, uncontrolled heart failure, or when pregnancy is confirmed unless the diagnostic benefit justifies the risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetrofosmin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT